Navigation Links
Generic Growth Strategies
Date:8/15/2013

DUBLIN, August 15, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/fcrtlb/generic_growth) has announced the addition of the "Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs

Generic Giants Strategize to Exploit Massive Patent Cliff Potential

Huge rewards and strong competition are prompting generic drug manufacturers to closely examine the best way to maximize market share as the industry patent cliff approaches its peak, states a new report from business intelligence analysts.

According to the firm's latest report, the revenues of drugs subject to patent expiration between 2013 and 2020 are valued at over US$100 billion, offering producers of generics and biosimilars a fantastic opportunity to substantially bolster their own sales.

However, while the next few years hold great promise for these companies, fierce competition exists not only from rival generics manufacturers, but also from major pharmaceutical players looking to maintain market dominance with Authorized Generics' (AG). In response, generics firms are re-evaluating their approach to the market.

Research states that companies such as Hospira are reaching out to new locales in order to build a global presence, while targeting governments looking to bring down healthcare costs. Exploiting pharmaceutically underdeveloped economies may allow generics firms to launch products first, challenging the intellectual property of proprietary pharmaceutical majors.

Generics producers also hope to capitalize on expiring patents by manufacturing complex generics that are difficult to reproduce. These super generics have high barriers to entry, a greater price than most other generics and incur greater Research and Development (R&D) costs; however, there is significant potential for super generics within specific therapeutic areas, such as cancer and conditions involving the central nervous system.

Research expects demand for high-quality generics to increase in the future, as key drugs lose patent protection and governments are offered opportunities to provide vital treatments at significantly reduced costs.

Key Topics Covered:

1.1 List of Tables
1.2 List of Figures

2 Generic Growth Strategies - Introduction

3 Generic Growth Strategies - Market Overview

4 Generic Growth Strategies - Regulatory Landscape

5 Generic Growth Strategies - Major Strategies

6 Generic Growth Strategies - Competitive Landscape

7 Generic Growth Strategies - Conclusion

8 Generic Growth Strategies - Appendix

Companies Mentioned

- Teva Pharmaceutical Industries Limited
- Sandoz
- Mylan
- Watson
- Actavis
- Hospira
- Sanofi
- Daiichi Sankyo
- Aspen
- STADA

For more information visit http://www.researchandmarkets.com/research/fcrtlb/generic_growth

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
3. Mylan Launches Generic Lipitor® in Five European Countries
4. Mylan Launches Generic Version of Plavix® Tablets
5. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
6. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Sihuans First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
10. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
11. Mylan Launches Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):